Azacytidine prevents experimental xenogeneic graft-versus-host disease without abrogating graft-versus-leukemia effects

The demethylating agent 5-azacytidine (AZA) has proven its efficacy in the treatment of myelodysplastic syndrome and acute myeloid leukemia. In addition, AZA can demethylate FOXP3 intron 1 (FOXP3i1) leading to the generation of regulatory T cells (Treg). Here, we investigated the impact of AZA on xe...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncoimmunology
Main Authors: Ehx, Grégory, Fransolet, Gilles, de Leval, Laurence, D'Hondt, Stéphanie, Lucas, Sophie, Hannon, Muriel, Delens, Loïc, Dubois, Sophie, Drion, Pierre, Beguin, Yves, Humblet-Baron, Stéphanie, Baron, Frédéric
Formato: Artigo
Idioma:Inglês
Publicado em: Taylor & Francis 2017
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5467988/
https://ncbi.nlm.nih.gov/pubmed/28638744
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2017.1314425
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados